MX370780B - Compuestos como moduladores de ror gamma. - Google Patents

Compuestos como moduladores de ror gamma.

Info

Publication number
MX370780B
MX370780B MX2016013342A MX2016013342A MX370780B MX 370780 B MX370780 B MX 370780B MX 2016013342 A MX2016013342 A MX 2016013342A MX 2016013342 A MX2016013342 A MX 2016013342A MX 370780 B MX370780 B MX 370780B
Authority
MX
Mexico
Prior art keywords
compounds
modulators
ror gamma
ror
modulation
Prior art date
Application number
MX2016013342A
Other languages
English (en)
Other versions
MX2016013342A (es
Inventor
Wu Lifen
Richard Brunette Steven
Robert Turner Michael
Zhang Qiang
Liang Shuang
Owen Hughes Robert
Bakonyi Johanna
Collin Delphine
Li Xian
Sibley Robert
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2016013342A publication Critical patent/MX2016013342A/es
Publication of MX370780B publication Critical patent/MX370780B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención comprende compuestos de la fórmula (I) (ver Fórmula) en donde las variables se definen en la presente que son apropiadas para la modulación de ROR? y el tratamiento de enfermedades relacionadas con la modulación de ROR?. La presente invención también comprende procesos de preparación de compuestos de la fórmula (I) y preparaciones farmacéuticas que los contienen.
MX2016013342A 2014-04-14 2015-04-10 Compuestos como moduladores de ror gamma. MX370780B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461979231P 2014-04-14 2014-04-14
PCT/US2015/025328 WO2015160654A1 (en) 2014-04-14 2015-04-10 Compounds as modulators of ror gamma

Publications (2)

Publication Number Publication Date
MX2016013342A MX2016013342A (es) 2017-01-26
MX370780B true MX370780B (es) 2020-01-03

Family

ID=52998264

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013342A MX370780B (es) 2014-04-14 2015-04-10 Compuestos como moduladores de ror gamma.

Country Status (35)

Country Link
US (5) US9242989B2 (es)
EP (2) EP3131902B1 (es)
JP (2) JP6282759B2 (es)
KR (2) KR102410076B1 (es)
CN (3) CN106132965B (es)
AP (1) AP2016009403A0 (es)
AR (2) AR100058A1 (es)
AU (2) AU2015247983B2 (es)
BR (2) BR112016021962A2 (es)
CA (1) CA2944787C (es)
CL (1) CL2016002421A1 (es)
CY (1) CY1122012T1 (es)
DK (1) DK3131902T3 (es)
EA (2) EA031351B1 (es)
ES (1) ES2744299T3 (es)
HR (1) HRP20191579T1 (es)
HU (1) HUE045847T2 (es)
IL (2) IL247419B (es)
LT (1) LT3131902T (es)
MA (1) MA46373A (es)
ME (1) ME03513B (es)
MX (1) MX370780B (es)
MY (1) MY182834A (es)
NZ (1) NZ723530A (es)
PE (2) PE20161572A1 (es)
PH (2) PH12016502019B1 (es)
PL (1) PL3131902T3 (es)
PT (1) PT3131902T (es)
RS (1) RS59170B1 (es)
SG (1) SG11201608537SA (es)
SI (1) SI3131902T1 (es)
TW (2) TWI655192B (es)
UA (2) UA120094C2 (es)
UY (1) UY36077A (es)
WO (1) WO2015160654A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3131902T (lt) 2014-04-14 2019-09-25 Boehringer Ingelheim International Gmbh Junginiai, kaip ror-gama moduliatoriai
FR3030518B1 (fr) * 2014-12-19 2018-03-23 Galderma Research & Development Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t)
DK3294713T5 (da) 2015-05-15 2021-05-31 Aurigene Discovery Tech Ltd Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
EP3356366B1 (en) 2015-10-01 2019-08-28 Boehringer Ingelheim International GmbH Pteridine derivatives as modulators of ror gamma
TWI728017B (zh) 2015-12-15 2021-05-21 瑞典商阿斯特捷利康公司 異吲哚化合物、包含其之醫藥組成物及其用途
WO2017127375A1 (en) * 2016-01-20 2017-07-27 Boehringer Ingelheim International Gmbh Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
US20200031753A1 (en) 2017-04-06 2020-01-30 Boehringer Ingelheim International Gmbh Cyclopropyl alkyl amines and process for their preparation
JP2020524660A (ja) 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド
CN109206346A (zh) * 2017-07-01 2019-01-15 复旦大学 叔胺类衍生物或其盐及其制备方法和用途
CN107903263B (zh) * 2017-12-28 2019-11-12 山东铂源药业有限公司 一种帕布昔利布中间体的合成方法
MY208400A (en) 2018-05-03 2025-05-07 Shanghai hengrui pharmaceutical co ltd Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
CN112930336A (zh) 2018-10-18 2021-06-08 勃林格殷格翰国际有限公司 光学活性的1-环丙基烷基-1-胺的可放大合成
CN116574099A (zh) 2019-09-23 2023-08-11 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
WO2021083311A1 (zh) 2019-10-31 2021-05-06 江苏恒瑞医药股份有限公司 一种RORγ调节剂的酸加成盐
WO2022106551A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Co-crystals of a ror gamma inhibitor
WO2022106548A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Solid forms of a ror gamma inhibitor
WO2022106550A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline polymorphic form of a ror gamma inhibitor
WO2022106549A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Crystalline salts of a ror gamma inhibitor
WO2022106547A1 (en) 2020-11-19 2022-05-27 Boehringer Ingelheim International Gmbh Process for synthesising a ror gamma inhibitor
CN117003757A (zh) * 2022-05-07 2023-11-07 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
CN116178279A (zh) * 2023-03-15 2023-05-30 上海药坦药物研究开发有限公司 一种5-溴-4-环丙基-6-甲氧基嘧啶及其中间体的制备方法
AU2024267864A1 (en) * 2023-05-09 2025-11-06 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
WO2009022185A2 (en) * 2007-08-16 2009-02-19 Astrazeneca Ab 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
BRPI0919844A2 (pt) 2008-09-26 2019-09-24 Boehringer Ingelheim Int compostos de azaindazol como antagonistas do receptor ccr1
PE20121433A1 (es) 2009-10-21 2012-11-10 Boehringer Ingelheim Int Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1
AU2012262014B2 (en) * 2011-06-01 2016-07-14 Janus Biotherapeutics, Inc. Novel immune system modulators
CN106008511B (zh) * 2012-05-14 2018-08-14 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
LT3131902T (lt) * 2014-04-14 2019-09-25 Boehringer Ingelheim International Gmbh Junginiai, kaip ror-gama moduliatoriai
EP3356366B1 (en) * 2015-10-01 2019-08-28 Boehringer Ingelheim International GmbH Pteridine derivatives as modulators of ror gamma
WO2017127375A1 (en) * 2016-01-20 2017-07-27 Boehringer Ingelheim International Gmbh Pyrazinedihydropyrimidinone or pyridazinedihydropyrimidinone compounds as modulators of ror gamma

Also Published As

Publication number Publication date
PE20211002A1 (es) 2021-06-01
CY1122012T1 (el) 2020-10-14
HUE045847T2 (hu) 2020-01-28
PH12020500252A1 (en) 2021-07-26
HK1244800A1 (zh) 2018-08-17
AP2016009403A0 (en) 2016-08-31
JP2018065874A (ja) 2018-04-26
CN107266454A (zh) 2017-10-20
UA120094C2 (uk) 2019-10-10
CN106132965B (zh) 2020-02-07
KR20160142396A (ko) 2016-12-12
HRP20191579T1 (hr) 2019-11-29
IL263878B (en) 2019-11-28
US20150291607A1 (en) 2015-10-15
EP3418280A1 (en) 2018-12-26
AU2019203027A1 (en) 2019-05-23
TW201841915A (zh) 2018-12-01
HK1244801A1 (zh) 2018-08-17
US20170008894A1 (en) 2017-01-12
PH12016502019A1 (en) 2017-01-09
EA201691978A1 (ru) 2017-02-28
LT3131902T (lt) 2019-09-25
TW201625622A (zh) 2016-07-16
BR112016021962A2 (pt) 2023-01-20
BR122020020657B1 (pt) 2022-12-20
AU2019203027B2 (en) 2020-07-09
CA2944787C (en) 2023-03-14
JP6463855B2 (ja) 2019-02-06
MX2016013342A (es) 2017-01-26
KR102410076B1 (ko) 2022-06-22
CN106132965A (zh) 2016-11-16
KR102410069B1 (ko) 2022-06-20
MA46373A (fr) 2019-08-07
EP3418280B1 (en) 2023-07-12
AU2015247983A1 (en) 2016-09-08
CA2944787A1 (en) 2015-10-22
CN107266450A (zh) 2017-10-20
RS59170B1 (sr) 2019-10-31
EA031351B1 (ru) 2018-12-28
DK3131902T3 (da) 2019-09-02
SI3131902T1 (sl) 2019-10-30
JP6282759B2 (ja) 2018-02-21
US9242989B2 (en) 2016-01-26
US9598415B2 (en) 2017-03-21
TWI652268B (zh) 2019-03-01
JP2017511357A (ja) 2017-04-20
IL247419B (en) 2019-03-31
IL263878A (en) 2019-01-31
PH12016502019B1 (en) 2020-10-23
AU2015247983B2 (en) 2019-05-16
MY182834A (en) 2021-02-05
CL2016002421A1 (es) 2017-03-24
EP3131902A1 (en) 2017-02-22
US20190002465A1 (en) 2019-01-03
US20180022749A1 (en) 2018-01-25
UY36077A (es) 2015-10-30
CN107266450B (zh) 2020-07-24
TWI655192B (zh) 2019-04-01
WO2015160654A1 (en) 2015-10-22
BR112016021962B1 (pt) 2022-12-13
PT3131902T (pt) 2019-09-17
EA201890329A1 (ru) 2018-07-31
PE20161572A1 (es) 2017-02-01
UA121255C2 (uk) 2020-04-27
EP3131902B1 (en) 2019-06-12
AR100058A1 (es) 2016-09-07
PL3131902T3 (pl) 2019-11-29
EA035063B1 (ru) 2020-04-23
KR20200040917A (ko) 2020-04-20
AR119454A2 (es) 2021-12-22
NZ723530A (en) 2023-05-26
ME03513B (me) 2020-04-20
CN107266454B (zh) 2019-08-09
SG11201608537SA (en) 2016-11-29
US20160075706A1 (en) 2016-03-17
ES2744299T3 (es) 2020-02-24

Similar Documents

Publication Publication Date Title
PH12020500252A1 (en) Compounds as modulators of ror gamma
MY197440A (en) Heteroamatic compounds as btk inhibitors
SG10201810879VA (en) Pharmaceutical compounds
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2019014876A (es) Compuestos heteroaromaticos como inhibidores de vanina.
NZ761519A (en) Nlrp3 modulators
MX377329B (es) Moduladores de ror gamma (ror?).
MX374728B (es) MODULADORES DE ROR GAMMA (RORy).
IL248668B (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
MX378111B (es) Moduladores de ror gamma (ror?).
PH12016501613A1 (en) Pyrazines modulators of gpr6
IL248670A0 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
MX2017007380A (es) Compuestos organicos.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs

Legal Events

Date Code Title Description
FG Grant or registration